Table 4.
Prevalence ratios (PR) and 95% CIs for frailty status of participants with serum 25-hydroxyvitamin D concentrations < 50 versus ≥ 50 nmol/L
| Serum 25-hydroxyvitamin D | n | ||
|---|---|---|---|
| < 50 nmol/L | ≥ 50 nmol/L | ||
| PR (95% CI) | Reference group | ||
| Frail vs. non-frail | |||
| Model 1 | 2.24 (1.06; 4.75)* | 1 (ref) | 458 |
| Model 2 | 2.07 (1.02; 4.20)* | 1 (ref) | 458 |
| Model 3 | 2.30 (1.11; 4.76)* | 1 (ref) | 453 |
| Pre-frail vs. non-frail | |||
| Model 1 | 1.10 (0.91; 1.32) | 1 (ref) | 714 |
| Model 2 | 1.08 (0.90; 1.29) | 1 (ref) | 714 |
| Model 3 | 1.06 (0.88; 1.26) | 1 (ref) | 711 |
| Pre-frail or frail vs. non-frail | |||
| Model 1 | 1.14 (0.97; 1.35) | 1 (ref) | 747 |
| Model 2 | 1.13 (0.96; 1.32) | 1 (ref) | 747 |
| Model 3 | 1.10 (0.93; 1.29) | 1 (ref) | 742 |
Analyzed by Cox Proportional Hazards analysis
Model 1 adjusted for age, sex and laboratory site, Model 2 adjusted for age, sex, laboratory site, BMI and season, Model 3 adjusted for age, sex, laboratory site, BMI, season, ethnicity, alcohol, smoking and number of diseases. Models are not corrected for physical activity, as this measure is also included in frailty status
*P < 0.05